Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Suspension Processing of Microporous Metal-Organic Frameworks: A Scalable Route to High-Quality Adsorbents.

Kirchon A, Day GS, Fang Y, Banerjee S, Ozdemir OK, Zhou HC.

iScience. 2018 Jul 27;5:30-37. doi: 10.1016/j.isci.2018.06.009. Epub 2018 Jul 11.

2.

Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions.

Day GS, Musiek ES, Morris JC.

Alzheimer Dis Assoc Disord. 2018 Sep 14. doi: 10.1097/WAD.0000000000000276. [Epub ahead of print]

PMID:
30222606
3.

Incorporating Heavy Alkanes in Metal-Organic Frameworks for Optimizing Adsorbed Natural Gas Capacity.

Fang Y, Banerjee S, Joseph EA, Day GS, Bosch M, Li J, Wang Q, Drake H, Ozdemir OK, Ornstein JM, Wang Y, Lu TB, Zhou HC.

Chemistry. 2018 Sep 10. doi: 10.1002/chem.201804012. [Epub ahead of print]

PMID:
30203519
4.

Author response: Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, Gronseth GS, Marson D, Pringsheim T, Day GS, Sager M, Stevens J, Rae-Grant A.

Neurology. 2018 Aug 21;91(8):373-374. doi: 10.1212/WNL.0000000000006042. No abstract available.

PMID:
30126885
5.

Identifying priority outcomes that influence selection of disease-modifying therapies in MS.

Day GS, Rae-Grant A, Armstrong MJ, Pringsheim T, Cofield SS, Marrie RA.

Neurol Clin Pract. 2018 Jun;8(3):179-185. doi: 10.1212/CPJ.0000000000000449.

PMID:
30105155
6.

Exposed Equatorial Positions of Metal Centers via Sequential Ligand Elimination and Installation in MOFs.

Yuan S, Zhang P, Zhang L, Garcia-Esparza AT, Sokaras D, Qin JS, Feng L, Day GS, Chen W, Drake HF, Elumalai P, Madrahimov ST, Sun D, Zhou HC.

J Am Chem Soc. 2018 Aug 29;140(34):10814-10819. doi: 10.1021/jacs.8b04886. Epub 2018 Aug 21.

PMID:
30089362
7.

Discovery and validation of autosomal dominant Alzheimer's disease mutations.

Hsu S, Gordon BA, Hornbeck R, Norton JB, Levitch D, Louden A, Ziegemeier E, Laforce R Jr, Chhatwal J, Day GS, McDade E, Morris JC, Fagan AM, Benzinger TLS, Goate AM, Cruchaga C, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN), Karch CM.

Alzheimers Res Ther. 2018 Jul 18;10(1):67. doi: 10.1186/s13195-018-0392-9.

8.

Autoimmune Dementia.

Long JM, Day GS.

Semin Neurol. 2018 Jun;38(3):303-315. doi: 10.1055/s-0038-1660480. Epub 2018 Jul 16.

PMID:
30011411
9.

Long-Term Cognitive Outcomes in Patients with Autoimmune Encephalitis.

Hébert J, Day GS, Steriade C, Wennberg RA, Tang-Wai DF.

Can J Neurol Sci. 2018 Sep;45(5):540-544. doi: 10.1017/cjn.2018.33. Epub 2018 Jun 25.

PMID:
29936915
10.

Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T.

Neurology. 2018 Apr 24;90(17):789-800. doi: 10.1212/WNL.0000000000005345.

PMID:
29686117
11.

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T.

Neurology. 2018 Apr 24;90(17):777-788. doi: 10.1212/WNL.0000000000005347.

PMID:
29686116
12.

Autoimmune Encephalitis With Multiple Autoantibodies: A Diagnostic and Therapeutic Challenge.

Kim AE, Kang P, Bucelli RC, Ferguson CJ, Schmidt RE, Varadhachary AS, Day GS.

Neurologist. 2018 Mar;23(2):55-59. doi: 10.1097/NRL.0000000000000171.

PMID:
29494437
13.

Positive Allosteric Modulation as a Potential Therapeutic Strategy in Anti-NMDA Receptor Encephalitis.

Warikoo N, Brunwasser SJ, Benz A, Shu HJ, Paul SM, Lewis M, Doherty J, Quirk M, Piccio L, Zorumski CF, Day GS, Mennerick S.

J Neurosci. 2018 Mar 28;38(13):3218-3229. doi: 10.1523/JNEUROSCI.3377-17.2018. Epub 2018 Feb 23.

14.

In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease.

Day GS, Gordon BA, Perrin RJ, Cairns NJ, Beaumont H, Schwetye K, Ferguson C, Sinha N, Bucelli R, Musiek ES, Ghoshal N, Ponisio MR, Vincent B, Mishra S, Jackson K, Morris JC, Benzinger TLS, Ances BM.

Neurology. 2018 Mar 6;90(10):e896-e906. doi: 10.1212/WNL.0000000000005064. Epub 2018 Feb 7.

PMID:
29438042
15.

Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, Gronseth GS, Marson D, Pringsheim T, Day GS, Sager M, Stevens J, Rae-Grant A.

Neurology. 2018 Jan 16;90(3):126-135. doi: 10.1212/WNL.0000000000004826. Epub 2017 Dec 27.

PMID:
29282327
16.

Teaching NeuroImages: Cerebral amyloid angiopathy-related inflammation presenting with isolated leptomeningitis.

Kang P, Bucelli RC, Ferguson CJ, Corbo JC, Kim AH, Day GS.

Neurology. 2017 Aug 8;89(6):e66-e67. doi: 10.1212/WNL.0000000000004218. No abstract available.

PMID:
28784645
17.

Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnestic Alzheimer Disease Dementia.

Day GS, Gordon BA, Jackson K, Christensen JJ, Rosana Ponisio M, Su Y, Ances BM, Benzinger TLS, Morris JC.

Alzheimer Dis Assoc Disord. 2017 Apr-Jun;31(2):87-93. doi: 10.1097/WAD.0000000000000196.

18.

Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease.

Day GS, Lim TS, Hassenstab J, Goate AM, Grant EA, Roe CM, Cairns NJ, Morris JC.

Neurology. 2017 Mar 28;88(13):1273-1281. doi: 10.1212/WNL.0000000000003770. Epub 2017 Feb 24.

19.

Rethinking Outcomes in Leucine-Rich, Glioma-Inactivated 1 Protein Encephalitis: "Good" Isn't Good Enough.

Day GS.

JAMA Neurol. 2017 Jan 1;74(1):19-21. doi: 10.1001/jamaneurol.2016.4538. No abstract available.

PMID:
27893010
20.

A Case Study in the History of Neurology.

Day GS, Tang-Wai DF, Shamy MC.

Neurohospitalist. 2016 Oct;6(4):181-184. Epub 2016 May 27.

21.

Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study.

Day GS, Musiek ES, Roe CM, Norton J, Goate AM, Cruchaga C, Cairns NJ, Morris JC.

JAMA Neurol. 2016 Sep 1;73(9):1125-32. doi: 10.1001/jamaneurol.2016.1236.

23.

Anti N-methyl-D-aspartate receptor encephalitis: a game-changer?

Fischer CE, Golas AC, Schweizer TA, Munoz DG, Ismail Z, Qian W, Tang-Wai DF, Rotstein DL, Day GS.

Expert Rev Neurother. 2016 Jul;16(7):849-59. doi: 10.1080/14737175.2016.1184088. Epub 2016 May 17. Review.

PMID:
27123777
24.

N-methyl-D-aspartate receptor encephalitis mediates loss of intrinsic activity measured by functional MRI.

Brier MR, Day GS, Snyder AZ, Tanenbaum AB, Ances BM.

J Neurol. 2016 Jun;263(6):1083-91. doi: 10.1007/s00415-016-8083-6. Epub 2016 Mar 30.

25.

Teaching NeuroImages: Recurrent SSPE presenting as Anton syndrome with cortical ribboning.

Day GS, Tai P, Moharir M, Tang-Wai DF.

Neurology. 2015 Nov 10;85(19):e141-2. doi: 10.1212/WNL.0000000000002096. No abstract available.

26.

GRIN1 polymorphisms do not affect susceptibility or phenotype in NMDA receptor encephalitis.

Day GS, Prüss H, Benseler SM, Paton TA, Paterson AD, Andrade DM.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 24;2(5):e153. doi: 10.1212/NXI.0000000000000153. eCollection 2015 Oct.

27.

Fanning the Flames in Anti-N-methyl-D-aspartate Receptor Encephalitis.

Day GS, Munoz DG.

Int J Gynecol Pathol. 2015 Jul;34(4):401-2. doi: 10.1097/PGP.0000000000000186. No abstract available.

PMID:
26068021
28.

Cognitive decline in an older physician.

Day GS, Carette S, Tang-Wai DF.

CMAJ. 2015 Jul 14;187(10):750-4. doi: 10.1503/cmaj.140589. Epub 2015 Mar 30. No abstract available.

29.

Thiamine prescribing practices within university-affiliated hospitals: a multicenter retrospective review.

Day GS, Ladak S, Curley K, Farb NA, Masiowski P, Pringsheim T, Ritchie M, Cheung A, Jansen S, Methot L, Neville HL, Bates D, Lowe D, Fernandes N, Ferland A, Martin del Campo C.

J Hosp Med. 2015 Apr;10(4):246-53. doi: 10.1002/jhm.2324. Epub 2015 Feb 3.

PMID:
25652810
30.

Abnormal neurons in teratomas in NMDAR encephalitis.

Day GS, Laiq S, Tang-Wai DF, Munoz DG.

JAMA Neurol. 2014 Jun;71(6):717-24. doi: 10.1001/jamaneurol.2014.488.

PMID:
24781184
31.

When dementia progresses quickly: a practical approach to the diagnosis and management of rapidly progressive dementia.

Day GS, Tang-Wai DF.

Neurodegener Dis Manag. 2014;4(1):41-56. doi: 10.2217/nmt.13.75. Review.

PMID:
24640978
32.

Lateral medullary syndrome: a diagnostic approach illustrated through case presentation and literature review.

Day GS, Swartz RH, Chenkin J, Shamji AI, Frost DW.

CJEM. 2014 Mar;16(2):164-70. Review.

PMID:
24626124
33.

LGI1 autoantibodies associated with cerebellar degeneration.

Steriade C, Day GS, Lee L, Murray BJ, Fritzler MJ, Keith J.

Neuropathol Appl Neurobiol. 2014 Aug;40(5):645-9. doi: 10.1111/nan.12132. No abstract available.

PMID:
24606111
34.

The rapidly expanding world of rapidly progressive encephalopathy.

Day GS, Benseler SM.

Ann Neurol. 2014 Mar;75(3):334-6. doi: 10.1002/ana.24010. Epub 2014 Mar 13. No abstract available.

PMID:
24038326
35.

Wernicke encephalopathy: a medical emergency.

Day GS, del Campo CM.

CMAJ. 2014 May 13;186(8):E295. doi: 10.1503/cmaj.130091. Epub 2013 Sep 9. Review. No abstract available.

36.

Salience network resting-state activity: prediction of frontotemporal dementia progression.

Day GS, Farb NA, Tang-Wai DF, Masellis M, Black SE, Freedman M, Pollock BG, Chow TW.

JAMA Neurol. 2013 Oct;70(10):1249-53.

PMID:
23959214
37.

Anti-NMDA receptor encephalitis in children: the disorder, its diagnosis, and treatment.

Peery HE, Day GS, Doja A, Xia C, Fritzler MJ, Foster WG.

Handb Clin Neurol. 2013;112:1229-33. doi: 10.1016/B978-0-444-52910-7.00045-3. Review.

PMID:
23622333
38.

Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology.

Peery HE, Day GS, Dunn S, Fritzler MJ, Prüss H, De Souza C, Doja A, Mossman K, Resch L, Xia C, Sakic B, Belbeck L, Foster WG.

Autoimmun Rev. 2012 Oct;11(12):863-72. doi: 10.1016/j.autrev.2012.03.001. Epub 2012 Mar 11. Review.

PMID:
22440397
39.

Investigating the role of the superior colliculus in active vision with the visual search paradigm.

Shen K, Valero J, Day GS, Paré M.

Eur J Neurosci. 2011 Jun;33(11):2003-16. doi: 10.1111/j.1460-9568.2011.07722.x. Review.

PMID:
21645096
40.

Anti-NMDA-receptor encephalitis: case report and literature review of an under-recognized condition.

Day GS, High SM, Cot B, Tang-Wai DF.

J Gen Intern Med. 2011 Jul;26(7):811-6. doi: 10.1007/s11606-011-1641-9. Epub 2011 Feb 12. Review.

41.

Guilty as charged: non-innocent behavior by a pincer ligand featuring a central cationic phosphenium donor.

Day GS, Pan B, Kellenberger DL, Foxman BM, Thomas CM.

Chem Commun (Camb). 2011 Mar 28;47(12):3634-6. doi: 10.1039/c0cc05739h. Epub 2011 Feb 10.

PMID:
21311784
42.

Rosary-like pattern calcified lesions: an unusual manifestation of ipsilateral carotid artery stenosis.

Day GS, Desai J, Jin AY.

Cerebrovasc Dis. 2009;28(5):536. doi: 10.1159/000247027. Epub 2009 Oct 13. No abstract available.

43.
44.

Scanning the periphery.

Day GS, Schoemaker PJ.

Harv Bus Rev. 2005 Nov;83(11):135-40, 142, 144-8 passim.

PMID:
16299966
45.

Strategies for surviving a shakeout.

Day GS.

Harv Bus Rev. 1997 Mar-Apr;75(2):92-102.

PMID:
10165451

Supplemental Content

Support Center